Almost half of incident hyperkalemia events are followed by changes in RAAS inhibitor therapy.
Patients treated with the mineralocorticoid receptor antagonist had a higher frequency of moderate hyperkalemia compared with placebo recipients.
Elderly patients hospitalized for heart failure who have high serum potassium levels at admission are at increased risk of readmission for heart failure and death.
New model predicts that maintenance of normal potassium levels in CKD patients to optimize use of renin-angiotensin-aldosterone inhibitors can delay progression to ESRD and prolong survival.
In patients with severe hyperkalemia, the Brugada syndrome ECG phenotype is associated with a high prevalence of malignant arrhythmias and all-cause mortality.
Hyperkalemia developed in nearly 67% of hemodialysis patients during or immediately following total parathyroidectomy with autotransplantation for secondary hyperparathyroidism.
Spironolactone improved cardiovascular outcomes in heart failure patients with chronic kidney disease, but increased their risk of hyperkalemia.
Elevated serum potassium levels increased the risk for end-stage renal disease by approximately 30%, independent of decline in estimated glomerular filtration rate.
Sex, high and low baseline potassium levels, and reduced renal function independently predict hyper- and hypokalemia in patients with heart failure.
In a study, patiromer lowered serum phosphate in patients with hyperkalemia and hyperphosphatemia.